# One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

> **NCT03974425** · NA · COMPLETED · sponsor: **University of Alexandria** · enrollment: 37 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Aflibercept Injection [Eylea]

## Key facts

- **NCT ID:** NCT03974425
- **Lead sponsor:** University of Alexandria
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2017-04-01
- **Final completion:** 2018-04-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03974425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03974425, "One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03974425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*